Table S2.

Reasons to switch therapy during the 1-year follow-up period

	Change from VKA to other treatment n=14 of 85* (16.4%)	Change from dabigatran to other treatment n=22 of 76* (28.9%)	Change from rivaroxaban to other treatment n=4 of 35* (11.4%)
Physician’s concerns	Four patients	Eight patients	One patient
Patient’s concerns	–	–	–
Adverse events	Three patients	Eight patients	One patient
Costs of therapy	–	One patient	One patient
Other	Three patients	Eight patients	One patient
Reasons for medication change as	“Easier use of DOAC” (2×)	“Impaired renal function” (2×)	“Not well tolerated”
detailed by patient or caregiver	“Anemia attributed to VKA”	“Bleeding from gastric ulcers” (2×)
	“Labile INR” (4×)	“Dyspeptic symptoms” (2×)
	“VKA suspected as precipitating factor for psychotic episode”	“Easier use of a once daily regime” (2×)
		“Skin changes attributed to dabigatran”
		“Vertigo attributed to dabigatran”
		“Family doctor: no experience with dabigatran”

Notes:

^*Patients available at 1-year follow-up. Patients could provide more than one reason in the questionnaire.

Abbreviations: DOAC, direct oral anticoagulants; INR, international normalized ratio; VKA, vitamin K antagonists.